- Home
- NTRB vs BOLD Comparison
NTRB vs BOLD Comparison
Compare NTRB & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- BOLD
- Stock Information
- Founded
- NTRB 2016
- BOLD 2018
- Country
- NTRB United States
- BOLD United States
- Employees
- NTRB N/A
- BOLD N/A
- Industry
- NTRB Industrial Specialties
- BOLD
- Sector
- NTRB Health Care
- BOLD
- Exchange
- NTRB Nasdaq
- BOLD Nasdaq
- Market Cap
- NTRB 77.9M
- BOLD 81.0M
- IPO Year
- NTRB N/A
- BOLD 2024
- Fundamental
- Price
- NTRB $6.17
- BOLD $2.95
- Analyst Decision
- NTRB
- BOLD Strong Buy
- Analyst Count
- NTRB 0
- BOLD 3
- Target Price
- NTRB N/A
- BOLD $23.00
- AVG Volume (30 Days)
- NTRB 28.2K
- BOLD 57.8K
- Earning Date
- NTRB 12-11-2024
- BOLD 11-11-2024
- Dividend Yield
- NTRB N/A
- BOLD N/A
- EPS Growth
- NTRB N/A
- BOLD N/A
- EPS
- NTRB N/A
- BOLD N/A
- Revenue
- NTRB $1,803,816.00
- BOLD N/A
- Revenue This Year
- NTRB N/A
- BOLD N/A
- Revenue Next Year
- NTRB N/A
- BOLD N/A
- P/E Ratio
- NTRB N/A
- BOLD N/A
- Revenue Growth
- NTRB N/A
- BOLD N/A
- 52 Week Low
- NTRB $1.93
- BOLD $2.82
- 52 Week High
- NTRB $9.60
- BOLD $15.24
- Technical
- Relative Strength Index (RSI)
- NTRB 50.57
- BOLD N/A
- Support Level
- NTRB $5.24
- BOLD N/A
- Resistance Level
- NTRB $6.40
- BOLD N/A
- Average True Range (ATR)
- NTRB 0.71
- BOLD 0.00
- MACD
- NTRB -0.12
- BOLD 0.00
- Stochastic Oscillator
- NTRB 33.23
- BOLD 0.00
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.